C4 Therapeutics, Inc. — Director's Dealing 2021

Aug 20, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2021-07-02

Reporting Person: Dubin Glenn (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-02	Common Stock	A	157	$39.72	Acquired	157	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	770607	Indirect
Common Stock	20000	Indirect

Footnotes

F1: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.

F2: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 2, 2021.

F3: Shares held directly by DF Investment Partners LLC ("DFIP"). The Reporting Person serves as managing member of DFIP and may be deemed to exercise voting and investment power over the shares held by DFIP. The Reporting Person disclaims beneficial ownership of the shares held by DFIP except to the extent of his pecuniary interest therein.

F4: Shares held directly by G&E Dubin Family Foundation. The Reporting Person may be deemed to exercise voting and investment power over the shares held by G&E Dubin Family Foundation and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.